Efficacy and ctDNA analysis in an updated cohort of patients with TRK fusion lung cancer treated with larotrectinib

被引：0
|
作者：
Hoejgaard, M. [1 ]
Drilon, A. [2 ,3 ]
Lin, J. J. [4 ]
Kummar, S. [5 ]
Tan, D. S. W. [6 ]
Patel, J. [7 ]
Leyvraz, S. [8 ]
Garcia, V. Moreno [9 ]
Rosen, L. S. [10 ]
Solomon, B. [11 ]
Yachnin, J. [12 ]
Liu, Y. [13 ,14 ]
Dai, M-S. [15 ]
Norenberg, R. [16 ]
Burcoveanu, D-I. [17 ]
Yun, L. [18 ]
Beckmann, G. [19 ]
Mussi, C. E. [20 ]
Shen, L. [21 ]
机构：
[1] Rigshosp, Dept Oncol, Phase Unit 1, Copenhagen, Denmark
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Weill Cornell Med Coll, New York, NY USA
[4] MGH Massachusetts Gen Hosp, Thorac Oncol Dept, Boston, MA USA
[5] OHSU Knight Canc Inst, Div Hematol & Med Oncol, Ctr Hlth & Healing, Bldg 1 South Waterfront, Portland, OR USA
[6] NCCS Natl Canc Ctr Singapore, Med Oncol Dept, Singapore, Singapore
[7] Northwestern Univ, Dept Med, Chicago, IL USA
[8] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany
[9] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD Early Phase Clin Trials Unit, Madrid, Spain
[10] UCLA, Hematol Oncol Santa Monica, Santa Monica, CA USA
[11] Avera Canc Inst, Div Hematol & Oncol, Sioux Falls, SD USA
[12] Karolinska Univ Hosp, Dept Oncol, Solna, Sweden
[13] Sichuan Univ, West China Hosp, Ctr Canc, Dept Thorac Oncol, Chengdu, Peoples R China
[14] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China
[15] Tri Serv Gen Hosp, Divis Oncol, Taipei, Taiwan
[16] Chrestos Concept GmbH & Co KG, Stat, Essen, Germany
[17] Bayer Healthcare Pharmaceut Inc, Med Affairs Oncol, Basel, Switzerland
[18] Bayer HealthCare Pharmaceut Inc, Mississauga, ON, Canada
[19] Bayer AG Pharmaceut, Res & Dev Pharmaceut, Berlin, Germany
[20] Bayer SpA, Div Pharmaceut, Milan, Italy
[21] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15MO
引用
收藏
页码：S48 / S49
页数：2
相关论文
共 50 条
  • [21] Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer.
    Drilon, Alexander E.
    Kummar, Shivaani
    Lin, Jessica Jiyeong
    Tan, Daniel Shao-Weng
    Moreno, Victor
    Leyvraz, Serge
    Dubashi, Biswajit
    Haresh, K. P.
    Burcoveanu, Domnita-Ileana
    Neu, Natascha
    Mussi, Chiara E.
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Extended Follow-up of Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Lung Cancer
    Moreno, V.
    Lin, J. J.
    Tan, D. S. W.
    Kummar, S.
    Dai, M. -S.
    Lassen, U. N.
    Leyvraz, S.
    Liu, Y.
    Patel, J. D.
    Rosen, L.
    Solomon, B.
    Yachnin, J.
    Norenberg, R.
    Fellous, M.
    Mussi, C. E.
    Shen, L.
    Drilon, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S473 - S474
  • [23] Larotrectinib efficacy and safety in adult TRK fusion cancer patients.
    Hong, David S.
    Kummar, Shivaani
    Farago, Anna F.
    Lassen, Ulrik Niels
    Berlin, Jordan
    Schilder, Russell J.
    McDermott, Raymond S.
    Patel, Jyoti D.
    Dowlati, Afshin
    Doebele, Robert Charles
    Tan, Daniel Shao-Weng
    Lee, James J.
    Nanda, Shivani
    Childs, Barrett H.
    Ku, Nora
    Drilon, Alexander E.
    Hyman, David Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.
    van Tilburg, Cornelis Martinus
    DuBois, Steven G.
    Albert, Catherine Michelle
    Federman, Noah
    Nagasubramanian, Ramamoorthy
    Geoerger, Birgit
    Orbach, Daniel
    Bielack, Stefan S.
    Shukla, Neerav Narendra
    Turpin, Brian
    Casanova, Michela
    Spunt, Sheri L.
    Qamoos, Hope
    Nanda, Shivani
    Childs, Barrett H.
    Cox, Michael Craig
    Pappo, Alberto S.
    Laetsch, Theodore Willis
    Mascarenhas, Leo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Efficacy of larotrectinib in TRK fusion cancer in adults and children
    Blattmann, C.
    Drilon, A.
    Laetsch, T. W.
    Kummar, S.
    DuBois, S. G.
    Lassen, U. N.
    Demetri, G. D.
    Nathenson, M.
    Doebele, R. C.
    Farago, A. F.
    Pappo, A. S.
    Turpin, B.
    Dowlati, A.
    Brose, M. S.
    Mascarenhas, L.
    Federman, N.
    Berlin, J.
    El-Deiry, W. S.
    Baik, C.
    Deeken, J.
    Boni, V.
    Nagasubramanian, R.
    Taylor, M.
    Rudzinski, E. R.
    Meric-Bernstam, F.
    Sohal, D. P. S.
    Ma, P. C.
    Raez, L. E.
    Hechtman, J. F.
    Benayed, R.
    Ladanyi, M.
    Tuch, B. B.
    Ebata, K.
    Cruickshank, S.
    Ku, N. C.
    Cox, M. C.
    Hawkins, D. S.
    Hong, D. S.
    Hyman, D. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 154 - 155
  • [26] Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer
    Drilon, A.
    Lin, J.
    Lassen, U.
    Leyvraz, S.
    Liu, Y.
    Patel, J.
    Rosen, L.
    Solomon, B.
    Norenberg, R.
    Dima, L.
    Brega, N.
    Shen, L.
    Moreno, V.
    Kummar, S.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1125 - S1126
  • [27] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis
    Andre, T.
    Hong, D.
    Deeken, J.
    Italiano, A.
    Liu, T.
    Burcoveanu, D.
    Norenberg, R.
    Mussi, C.
    Xu, R.
    Drilon, A.
    Shen, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S12 - S13
  • [28] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
    Lin, Jessica Jiyeong
    Tan, Daniel Shao-Weng
    Kummar, Shivaani
    Patel, Jyoti D.
    Cermignani, Luciano
    Dai, Ming-Shen
    Lassen, Ulrik Niels
    Leyvraz, Serge
    Liu, Yongmei
    Moreno, Victor
    Rosen, Lee S.
    Saada-Bouzid, Esma
    Solomon, Benjamin Maurice
    Xu, Rui-Hua
    Yachnin, Jeffrey
    Norenberg, Ricarda
    Burcoveanu, Domnita-Ileana
    Mussi, Chiara E.
    Shen, Lin
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
    Rieke, D. T.
    Lin, Iyeong J.
    Tan, D. S.
    Kummar, S.
    Patel, J. D.
    Cermignani, L.
    Dai, M. -S.
    Lassen, U. N.
    Leyvraz, S.
    Liu, Y.
    Moreno, V.
    Rosen, L.
    Saada-Bouzid, E.
    Solomon, B.
    Xu, R. -H.
    Yachnin, J.
    Norenberg, R.
    Burcoveanu, D. -I.
    Mussi, C. E.
    Shen, L.
    Drilon, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 9 - 10
  • [30] Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
    Drilon, A.
    Shen, L.
    van Tilburg, C.
    Doz, F.
    Tan, D. S. W.
    Lin, J. J.
    Kummar, S.
    Lassen, U. N.
    McDermott, R. S.
    Dierselhuis, M. P.
    Albert, C. M.
    Nagasubramanian, R.
    Watt, T.
    Patil, T.
    Burcoveanu, D-I.
    Norenberg, R.
    Brega, N.
    Laetsch, T. W.
    Xu, R-H.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S470 - S470
12345